| Study | Family History (%) |
ER+ Tumors2 (%) |
HRT Use3 (%) |
Loss to Followup (%) |
Discontinuation of Study Drug (%) |
Women Who Took Tamoxifen for > 5 Years (n[%]) |
|
|---|---|---|---|---|---|---|---|
| Placebo | Treatment | ||||||
| Royal Marsden (19) | 100 | 63 | 26 | 11 | 31 | 40 | 79 (6.3) |
| Italian Study (21,23)1 | 21 | 43 | 14 | 0.6 | 25 | 28 | 77 (2.9) |
| 21 | Unk4 | 29 | NA | 34 | 36 | 2,462 (45) | |
| Breast Cancer Prevention Trial (20) | 76 | 71 | 0 | 1.6 | 20 | 24 | 2,424 (36.9) |
| Multiple Outcomes of Raloxifene Evaluation (22) | 12 | 60 | 10 | NA | 255 | 225 | Not applicable |
1First line refers to initial results published in 1998; second line refers to results with longer follow up published in 2002.
2ER+, estrogen receptor-positive.
3HRT, hormone replacement therapy.
4Unk, unknown; NA, data not available.
5Cumulative withdrawal at 36 months (includes loss to followup).